Search
                    Mississippi Paid Clinical Trials
A listing of 396  clinical trials  in Mississippi  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            277 - 288 of 396
        
                Mississippi is currently home to 396 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Jackson, Tupelo, Hattiesburg and Flowood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
                                
            
            
        Recruiting
                            
            
                The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/17/2025
            
            Locations: Southern Therapy and Advanced Research LLC (STAR), Jackson, Mississippi         
        
        
            
        
    
                
                                    National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
                                
            
            
        Recruiting
                            
            
                The purpose of this initiative is to improve care and outcomes for infants with HLHS by expanding the NPC-QIC national registry to gather clinical care process, outcome, and developmental data on infants with HLHS between diagnosis and 12 months of age, by improving the use of standards into everyday practice across pediatric cardiology centers, and by engaging parents as partners in the process.             
        
        
    Gender:
                ALL
            Ages:
                15 months and below
            Trial Updated:
                06/16/2025
            
            Locations: Batson Children's Hospital-University of Mississippi Medical Center, Jackson, Mississippi         
        
        
            Conditions: Hypoplastic Left Heart Syndrome (HLHS)
        
            
        
    
                
                                    Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
                                
            
            
        Recruiting
                            
            
                The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues.
The main questions it aims to answer are:
1. to determine if milrinone decreases the risk of death or PLCS within 7 days of the procedure, compared to standard treatment; and
2. to determine the effects of milrinone on two-year survival and neurodevelopmental outcome.             
        
        
    Gender:
                ALL
            Ages:
                3 months and below
            Trial Updated:
                06/13/2025
            
            Locations: University of Mississippi Medical Center, Jackson, Mississippi         
        
        
            Conditions: Post-ligation Cardiac Syndrome
        
            
        
    
                
                                    A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
                                
            
            
        Recruiting
                            
            
                The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/11/2025
            
            Locations: University Of Mississippi Medical Center, Jackson, Mississippi         
        
        
            Conditions: Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms
        
            
        
    
                
                                    Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.             
        
        
    Gender:
                FEMALE
            Ages:
                35 years and above
            Trial Updated:
                06/10/2025
            
            Locations: Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven, Mississippi         
        
        
            Conditions: Breast Cancer
        
            
        
    
                
                                    Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
                                
            
            
        Recruiting
                            
            
                The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma.
This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal flui...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                06/09/2025
            
            Locations: University of Mississippi Medical Center, Jackson, Mississippi         
        
        
            Conditions: Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
        
            
        
    
                
                                    A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
                                
            
            
        Recruiting
                            
            
                A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)             
        
        
    Gender:
                ALL
            Ages:
                50 years and above
            Trial Updated:
                06/06/2025
            
            Locations: Mississippi Retina Associates, Madison, Mississippi         
        
        
            Conditions: Wet Age-related Macular Degeneration
        
            
        
    
                
                                    Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir
                                
            
            
        Recruiting
                            
            
                This is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Pociredir in participants with sickle cell disease.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                06/05/2025
            
            Locations: Mississippi Center for Advanced Medicine, Madison, Mississippi         
        
        
            Conditions: Sickle Cell Disease, Sickle Cell Anemia
        
            
        
    
                
                                    A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
                                
            
            
        Recruiting
                            
            
                The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                06/04/2025
            
            Locations: 89bio Clinical Study Site, Flowood, Mississippi         
        
        
            Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
        
            
        
    
                
                                    Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
                                
            
            
        Recruiting
                            
            
                Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/04/2025
            
            Locations: Jackson Heart Clinic, Jackson, Mississippi         
        
        
            Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
        
            
        
    
                
                                    A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
                                
            
            
        Recruiting
                            
            
                The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).
In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain)...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/03/2025
            
            Locations: Velocity Clinical Research - MedPharmics - Gulfport, Gulfport, Mississippi         
        
        
            Conditions: SARS-CoV2, COVID-19
        
            
        
    
                
                                    Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
                                
            
            
        Recruiting
                            
            
                This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                05/30/2025
            
            Locations: Home-based telemedicine, Jackson, Mississippi         
        
        
            Conditions: Chronic Granulomatous Disease (CGD)
        
            
        
    